Understanding Mrd Testing In Cll

Thomas J. Kipps, MD, PhD, reviews the advantages and disadvantages of the different

With multiple options for frontline therapy in

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares her insights on the benefits and drawbacks of ...

In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, ...

Thomas J. Kipps, MD, PhD, discusses the value of

Measurable residual disease is playing a larger role in treatment assessment of

Experts discuss the importance of

While not yet mainstream in the community setting, measurable residual disease (

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, shares insights into ...

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, describes using

According to John Burke, MD, although

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of commercialized ...

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications ...

Thomas J. Kipps, MD, PhD, provides insight on the timepoints that

One of the current debates in

Thomas J. Kipps, MD, PhD, discusses the

Moving beyond acute lymphoblastic leukemia (ALL), experts review the use of

Thomas J. Kipps, MD, PhD, discusses the value of

MRD

Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the importance of measurable ...